JP2024538128A - Ehmt1及びehmt2の新規調節因子及びその治療用途 - Google Patents

Ehmt1及びehmt2の新規調節因子及びその治療用途 Download PDF

Info

Publication number
JP2024538128A
JP2024538128A JP2024522501A JP2024522501A JP2024538128A JP 2024538128 A JP2024538128 A JP 2024538128A JP 2024522501 A JP2024522501 A JP 2024522501A JP 2024522501 A JP2024522501 A JP 2024522501A JP 2024538128 A JP2024538128 A JP 2024538128A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
cycloalkyl
heteroalkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538128A5 (cg-RX-API-DMAC10.html
Inventor
ジョゼフ ピー. ヴァッカ,
ジョン ピー. マクスウェル,
ブレット ウィリアムズ,
ジョン エイチ. カム,
スコット スローナー,
Original Assignee
タンゴ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タンゴ セラピューティクス, インコーポレイテッド filed Critical タンゴ セラピューティクス, インコーポレイテッド
Publication of JP2024538128A publication Critical patent/JP2024538128A/ja
Publication of JP2024538128A5 publication Critical patent/JP2024538128A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024522501A 2021-10-15 2022-10-14 Ehmt1及びehmt2の新規調節因子及びその治療用途 Pending JP2024538128A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256057P 2021-10-15 2021-10-15
US63/256,057 2021-10-15
US202263390438P 2022-07-19 2022-07-19
US63/390,438 2022-07-19
PCT/US2022/046761 WO2023064586A1 (en) 2021-10-15 2022-10-14 Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof

Publications (2)

Publication Number Publication Date
JP2024538128A true JP2024538128A (ja) 2024-10-18
JP2024538128A5 JP2024538128A5 (cg-RX-API-DMAC10.html) 2025-10-21

Family

ID=84357982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522501A Pending JP2024538128A (ja) 2021-10-15 2022-10-14 Ehmt1及びehmt2の新規調節因子及びその治療用途

Country Status (9)

Country Link
US (1) US20240368139A1 (cg-RX-API-DMAC10.html)
EP (1) EP4416143A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024538128A (cg-RX-API-DMAC10.html)
KR (1) KR20240148310A (cg-RX-API-DMAC10.html)
AU (1) AU2022366869A1 (cg-RX-API-DMAC10.html)
CA (1) CA3234693A1 (cg-RX-API-DMAC10.html)
IL (1) IL311999A (cg-RX-API-DMAC10.html)
MX (1) MX2024004416A (cg-RX-API-DMAC10.html)
WO (1) WO2023064586A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116602242B (zh) * 2023-05-08 2024-01-23 中国水产科学研究院珠江水产研究所 一种提高反季鱼苗成活率的方法
WO2025155882A1 (en) * 2024-01-19 2025-07-24 Icahn School Of Medicine At Mount Sinai G9a/glp degradation / disruption compounds and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513778A (ja) * 2016-04-15 2019-05-30 エピザイム,インコーポレイティド Ehmt1およびehmt2阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP2020517618A (ja) * 2017-04-21 2020-06-18 エピザイム,インコーポレイティド Ehmt2阻害剤との併用療法
JP2021500326A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 血液障害の予防又は処置にehmt2阻害剤を使用する方法
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 免疫療法にehmt2阻害剤を使用する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
MA47233A (fr) * 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513778A (ja) * 2016-04-15 2019-05-30 エピザイム,インコーポレイティド Ehmt1およびehmt2阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
JP2020517618A (ja) * 2017-04-21 2020-06-18 エピザイム,インコーポレイティド Ehmt2阻害剤との併用療法
JP2021500326A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 血液障害の予防又は処置にehmt2阻害剤を使用する方法
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム,インコーポレイティド 免疫療法にehmt2阻害剤を使用する方法

Also Published As

Publication number Publication date
WO2023064586A1 (en) 2023-04-20
IL311999A (en) 2024-06-01
EP4416143A1 (en) 2024-08-21
AU2022366869A1 (en) 2024-05-02
US20240368139A1 (en) 2024-11-07
CA3234693A1 (en) 2023-04-20
MX2024004416A (es) 2024-07-09
KR20240148310A (ko) 2024-10-11

Similar Documents

Publication Publication Date Title
EP3788040B1 (en) Pyridazinones as parp7 inhibitors
US20230265116A1 (en) Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
AU2015232543B2 (en) 1,3-benzodioxole derivative
KR20250088505A (ko) 피리미딘-융합 고리 화합물, 및 이의 제조 방법 및 이의 용도
ES2940641T9 (es) Compuestos que inhiben la proteína MCL-1
JP2017178968A (ja) 化合物、その医薬組成物、及び癌治療用のidh1突然変異阻害薬としてのその使用
JP6522646B2 (ja) ROS1阻害剤としての置換4,5,6,7−テトラヒドロ−ピラゾロ[1,5−α]ピラジン誘導体および5,6,7,8−テトラヒドロ−4H−ピラゾロ[1,5−α][1,4]ジアゼピン誘導体
EP3442947A1 (en) Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
EA031223B1 (ru) Соединения, которые ингибируют белок mcl-1
KR20190017030A (ko) Dnmt1의 억제제로서의 치환된 피리딘
EP4055013B1 (en) Wdr5 inhibitors and modulators
JP2017508779A5 (cg-RX-API-DMAC10.html)
EP3781550A1 (en) Bicyclic carboxamides and methods of use thereof
UA129879C2 (uk) Макроциклічні інгібітори rip2-кінази
WO2023069731A1 (en) Compounds that mediate protein degradation and methods of use thereof
KR20240148310A (ko) Ehmt1 및 ehmt2의 신규 조절제 및 그의 치료 용도
CN118647610A (zh) Ehmt1和ehmt2的新型调节剂及其治疗用途
WO2026055780A1 (en) Compounds and compositions for treating mc4r related conditions
WO2026093360A1 (en) Tricyclic compounds for the treatment of cancer
WO2024216164A1 (en) N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer
HK40048232A (en) Pyridazinones as parp7 inhibitors
HK40048232B (en) Pyridazinones as parp7 inhibitors
HK40031697A (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
HK40031697B (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260803